Loading
A phase 1/2 trial of Eflornithine, Fulvestrant, Capivasertib in melanoma and skin cancer, run by Aminex Therapeutics, Inc., now recruiting.
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07287917 by Aminex Therapeutics, Inc., with 92 participants planned, started 2026-01-26 and due to reach its primary completion in 2028-02-28. Interventions recorded: AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab. Conditions listed: Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fulvestrant, UCSF Helen Diller Family Comprehensive Cancer Center.
Shares Capivasertib, Fulvestrant, UCSF Helen Diller Family Comprehensive Cancer Center.
Shares Capivasertib, Fulvestrant.
Shares Capivasertib, Fulvestrant.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Melanoma.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Pembrolizumab.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Pembrolizumab.
Shares Fulvestrant, UCSF Helen Diller Family Comprehensive Cancer Center.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/